Berkeley, CA (Press Release) – Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the United States Patent and Trademark Office has issued a new composition of matter patent related to altered APRIL-binding anti­bodies, further enhancing the com­pany’s B-select intellectual property port­folio. Specifically, the granted claims cover BION-1301, Aduro’s first-in-class anti-APRIL anti­body being eval­u­ated in a Phase 1/2 dose escalation trial for the treat­ment of multiple myeloma.

“Blocking APRIL rep­re­sents a unique ap­proach to treating patients with multiple myeloma and we believe BION-1301 has poten­tial to treat a myriad of on­col­ogy indi­ca­tions as …

A pleasant Tuesday to you, myeloma world.

We hope your week has started well. We been away for longer than ex­pec­ted, work­ing through some of the more technical details of the articles we discuss in today's Myeloma Morning.

Most of today's report focuses on two research articles that were published last week. Both articles were published in the journal Blood, and both are valuable contributions to what we know about multiple myeloma. As a result, we devote quite a bit of space to summarizing each of the articles.

Those long summaries mean …